Scotiabank Upgrades Mirati Therapeutics to Sector Perform, Announces $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer has upgraded Mirati Therapeutics (NASDAQ:MRTX) from Sector Underperform to Sector Perform and announced a price target of $58.
October 09, 2023 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirati Therapeutics has been upgraded by Scotiabank from Sector Underperform to Sector Perform with a new price target of $58.
The upgrade from Scotiabank is a positive signal for Mirati Therapeutics. The new price target of $58 indicates an expected increase in the stock's value. This could lead to a short-term positive impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100